Ultrasound Stimulation of Pancreatic Beta Cells

超声刺激胰腺β细胞

基本信息

批准号：
8878256
负责人：
Vesna Zderic
金额：
$ 7.63万
依托单位：
GEORGE WASHINGTON UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2014
资助国家：
美国
起止时间：
2014-07-01 至 2017-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8878256
关键词：
Ablation Adipocytes Adrenal Glands Adverse effects Affect Amputation Atherosclerosis Beta Cell Blindness Blood Glucose Catecholamines Cattle Cell Membrane Permeability Cell physiology Cells Cessation of life Chromaffin Cells Chronic Clinical Trials Complex Coronary Arteriosclerosis Development Diabetes Mellitus Disease Dose Drug Formulations Effectiveness End stage renal failure Epidemic Epinephrine Failure Focused Ultrasound Gastrointestinal Hormones Glucose Goals Health Health Care Costs Hormones Human Human body Hyperglycemia Hyperlipidemia Hypertension Hypoglycemia Impairment Injection of therapeutic agent Insulin Insulin Resistance Kidney Diseases Lead Life Style Malignant Neoplasms Metabolic Metabolic Diseases Metformin Methods Modification Neuropathy Non-Insulin-Dependent Diabetes Mellitus Norepinephrine Obesity Operative Surgical Procedures Oral Pancreas Patients Peripheral Peripheral Vascular Diseases Pharmaceutical Preparations Prevalence Production Recommendation Reporting Retinal Diseases Risk Safety Smoking Stimulus Stroke Structure of beta Cell of islet Technology Testing Therapeutic Time Tissues Ultrasonic Therapy Ultrasonography United States Vision Weight Gain Work adiponectin analog blood glucose regulation cardiovascular risk factor combat design gastrointestinal glucagon-like peptide 1 hormone analog improved insulin secretion insulin sensitivity insulin sensitizing drugs interest novel novel strategies premature relating to nervous system release of sequestered calcium ion into cytoplasm research study response therapeutic target

项目摘要

DESCRIPTION (provided by applicant): Type 2 diabetes mellitus is a complex metabolic disease that has reached epidemic proportions in the United States and around the world. The prevalence of diabetes in the United States is approximately 8.3%; worldwide, there are about 150 million cases, a number expected to double in the next 20 years. Diabetes increases the risk of development of chronic complications including atherosclerotic vascular diseases (coronary artery disease, stroke and peripheral vascular disease), retinopathy, nephropathy and neuropathies. These complications result in premature death, vision impairment and blindness, end stage kidney disease and amputation as well as engendering enormous health care costs. Type 2 diabetes results from the interplay of multiple metabolic abnormalities including decreased insulin sensitivity of peripheral tissues and insufficient insulin secretion from pancreatic b-cells. Clinical trials have shown that intensive blood glucose control together with reduction of the other cardiovascular risk factors can reduce the development of chronic complications. However, controlling type 2 diabetes is often difficult. Many patients are poorly compliant with lifestyle change recommendations, and pharmacological management routinely requires complex therapy with multiple medications, and loses its effectiveness over time. Thus, there is a growing interest in finding alternative methods for the treatment of diabetes. The objective of this proposal is to explore a novel, non- pharmacological approach that utilizes the application of ultrasound energy to augment insulin release from pancreatic b-cells. Low-intensity therapeutic ultrasound has been utilized before in production of reversible changes in cell membrane permeability, modulation of neural tissues, and enhancement of release of the adiponectin hormone from adipose cells, and epinephrine and norepinephrine from adrenal cells. Our experiments will focus on determination of effectiveness and safety of ultrasound application in stimulation of insulin release from the pancreatic b-cells. If shown successful our approach may eventually lead to new methods in the treatment of diabetes and other secretory diseases.

描述（由申请人提供）：2 型糖尿病是一种复杂的代谢性疾病，在美国和世界各地已达到流行程度。美国糖尿病患病率约为 8.3%；全球范围内约有 1.5 亿例，预计未来 20 年这一数字将翻一番。糖尿病会增加慢性并发症的风险，包括动脉粥样硬化性血管疾病（冠状动脉疾病、中风和外周血管疾病）、视网膜病、肾病和神经病。这些并发症导致过早死亡、视力损害和失明、终末期肾病和截肢，并产生巨大的医疗费用。 2 型糖尿病是多种代谢异常相互作用的结果，包括外周组织胰岛素敏感性降低和胰腺 B 细胞胰岛素分泌不足。临床试验表明，加强血糖控制并减少其他心血管危险因素可以减少慢性并发症的发生。然而，控制 2 型糖尿病通常很困难。许多患者对生活方式改变建议的依从性较差，药物管理通常需要使用多种药物进行复杂的治疗，并且随着时间的推移会失去其有效性。因此，人们对寻找治疗糖尿病的替代方法越来越感兴趣。本提案的目的是探索一种新颖的非药理学方法，利用超声能量来增强胰腺 B 细胞的胰岛素释放。低强度治疗超声以前已用于产生细胞膜通透性的可逆变化、神经组织的调节以及增强脂肪细胞中脂联素激素以及肾上腺细胞中肾上腺素和去甲肾上腺素的释放。我们的实验将重点确定超声波应用刺激胰腺 B 细胞释放胰岛素的有效性和安全性。如果成功的话，我们的方法最终可能会带来治疗糖尿病和其他分泌性疾病的新方法。